Myc is an oncogene deregulated in most—perhaps all—human cancers. Each Myc family
member, c-, L-, and N-Myc, has been connected to tumor progression and maintenance …

More than 15 years have passed since stent technology was introduced by Sigwart et al.[U.
Sigwart, J. Puel, V. Mirkovitch, F. Joffe, et al. Intravascular stents to prevent occlusion and …

Percutaneous coronary intervention (PCI) has become the most common revascularization
procedure for coronary artery disease. The use of stents has reduced the rate of restenosis …

The water-soluble, biocompatible polymer poly (2-methacryloyloxyethyl phosphorylcholine)(
PMPC) was evaluated for protein conjugation. PMPC is a zwitterionic polymer that is able to …

This review focuses on new and emerging large-molecule bioactive agents delivered from
stent surfaces in drug-eluting stents (DESs) to inhibit vascular restenosis in the context of …

It is well known that, across all populations (based on geographic location, race, ethnicity,
age, and sex), coronary artery disease (CAD) is the single most common cause of death …

Neovascularization is associated with destabilization of atheromatic plaques. Increased
expression of vascular endothelial growth factor (VEGF) is important in the process of …

Percutaneous coronary intervention is the preferred revascularization approach for most
patients with coronary artery disease. However, this strategy is limited by renarrowing of the …

Drug-eluting stents are the treatment of choice for reducing restenosis rates after plaque
removal. The drugs in use today partition between the plasma phase and binding sites in the …

Despite the success of drug-eluting stents (DES) in reducing restenosis and the need for
target vessel revascularization, several deficiencies have been unraveled since their first …